2-Thiophen-2-ylpyrido[2,3-d][1,3]oxazin-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-Thiophen-2-ylpyrido[2,3-d][1,3]oxazin-4-one
• 化学式: C₁₁H₆N₂O₂S
• 分子量: 230.247
• InChiKey: TVTQQCOLZKBTCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  79.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-噻吩甲酰氯 、 2-氨基烟酸 在 吡啶 作用下， 反应 20.0h， 以61%的产率得到2-Thiophen-2-ylpyrido[2,3-d][1,3]oxazin-4-one
  参考文献：
  名称：

  Inhibitors of the tissue factor/factor VIIa-induced coagulation: synthesis and in vitro evaluation of novel 2-aryl substituted pyrido[3,4-d][1,3]-, pyrido[2,3-d][1,3]-, pyrazino[2,3-d][1,3]-, pyrimido[4,5-d][1,3]-, pyrazolo[3,4-d][1,3]-, thieno[3,2-d][1,3]- and thieno[2,3-d][1,3]-oxazin-4-ones

  摘要：

  The synthesis of a series of 2-aryl substituted hetero annulated 1,3-oxazin-4-ones and their evaluation as specific inhibitors of the tissue factor (TF)/factor VIIa (FVIIa)-induced pathway of coagulation is reported. Inhibitory activities (IC50 values) in the range 0.64 to > 40 muM on the activation of factor X (FX) by the TF/FVIIa complex were found for compounds having one or two electronegative substituents such as F and NO2 in the 2-aryl substituent. Some of the compounds showed a selectivity ratio towards FX and thrombin of > 50, thus being similar in specificity to 2-aryl substituted 4H-3,1-benzoxazin-4-ones described as potential drugs for oral antithrombotic treatment without side effects, such as bleeding, which is observed especially with thrombin inhibitors. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00207-8

文献信息

• [EN] HETEROCYCLIC COMPOUNDS REGULATING CLOTTING<br/>[FR] COMPOSES HETEROCYCLIQUES REGULANT LA COAGULATION
  申请人：NOVO NORDISK AS

  公开号：WO2000030646A1

  公开（公告）日：2000-06-02

  The invention relates to the use of heterocyclic compounds with formulas (I) and (II), and pharmaceutical acceptable salts thereof, for the manufacture of a pharmaceutical preparation for treatment of coagulation-related diseases. The compounds are inhibitors of TF-FVIIa activity and thus show anticoagulant activity. The invention also relates to methods of treatment. The invention furthermore relates to novel compounds with the formula (I) or (II).